For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Everyday Health on MSN
MASH: Is semaglutide right for you?
Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.
The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...
Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...
Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...
Zacks Investment Research on MSN
CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
FEELING achy, feverish or wiped out? As ‘superflu’ surges across the country, it might be easy to assume you’ve caught the ...
Pharmacists are urging people using weight loss injections to be alert to signs of dehydration as flu cases rise, warning ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results